Image Credit: Disney
Forgot password
Enter the email address you used when you joined and we'll send you instructions to reset your password.
If you used Apple or Google to create your account, this process will create a password for your existing account.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Reset password instructions sent. If you have an account with us, you will receive an email within a few minutes.
Something went wrong. Try again or contact support if the problem persists.
Morbius

‘Morbius’ delay partly down to ‘Spider-Man: No Way Home’ success

Part of Sony's reasoning to delay Morbius again was to free up more screens so Spider-Man: No Way Home can keep thriving.
This article is over 2 years old and may contain outdated information

Creative accounting is a regular practice in Hollywood, with the money men utilizing all sorts of tricks in an effort to make each year’s balance sheet as healthy as it can be.

Recommended Videos

Even though the surging Omicron variant was touted as the catalyst, the unstoppable success of Spider-Man: No Way Home has been cited as another major factor in the latest setback faced by Morbius.

The Marvel Cinematic Universe’s multiversal epic is one of the ten highest-grossing domestic releases ever, the 12th top-earning movie in history and the most lucrative superhero blockbuster that isn’t an Avengers team-up, so you can understand why Sony wouldn’t want to shoot itself in the foot.

No Way Home should pass $1.4 billion globally by the end of tomorrow at the latest, and it’s still got plenty of gas left in the tank. As per Deadline, the studio could simply be opting to play it safe by shunting Morbius back down the calendar to April 1, freeing up more screens for the third Spider-Man effort to continue hauling in those sweet, sweet box office dollars.

Morbius is by no means guaranteed to find huge success, but the No Way Home effect could lead to an uptick in takings it may have otherwise not enjoyed. Sony have regularly faced criticism for the handling of its comic book properties, but the latest shuffle for Jared Leto’s incoming antihero could yield increased commercial gains in the long run.


We Got This Covered is supported by our audience. When you purchase through links on our site, we may earn a small affiliate commission. Learn more about our Affiliate Policy
Author
Image of Scott Campbell
Scott Campbell
News, reviews, interviews. To paraphrase Keanu Reeves; Words. Lots of words.